From: Results of the observational prospective RealFLOT study
RealFLOT: Preoperative (n = 206) | RealFLOT: Postoperative (n = 142a) | Patients ≥ 65 in the preoperative phase (n = 89) | Patients < 65 in the preoperative phase (n = 117) | Patients ≥ 65 in the postoperative phase (n = 56a) | Patients < 65 in the postoperative phase (n = 86a) | |
---|---|---|---|---|---|---|
Hematologic AEs | ||||||
Neutropenia | 19.9% | 16.9% | 18.0% | 21.4% | 14.3% | 18.6% |
Febrile neutropenia | 4.4% | 1.4% | 4.5% | 4.3% | 1.8% | 1.2% |
Anemia | 0.5% | 0.7% | 0% | 0.8% | 0% | 1.2% |
Gastrointestinal AEs | ||||||
Diarrhea | 1.5% | 3.5% | 2.2% | 0.8% | 3.6% | 3.4% |
Stomatitis | 0.5% | 1.4% | 1.1% | 0% | 1.8% | 1.2% |
Nausea | 2.4% | 5.6% | 3.4% | 1.7% | 1.8% | 8.1% |
Vomiting | 1.9% | 3.5% | 4.5% | 0.8% | 1.8% | 4.6% |
Increases in ALT/AST | 0.5% | 0% | 0% | 0.8% | 0% | 0% |
Infective events (any G) | 5.8% | 3.5% | 5.6% | 6.0% | 5.4% | 2.3% |
Neurotoxic effects | 1% | 2.8% | 2.2% | 0% | 1.8% | 3.5% |
Cardiac complications | 0.5% | 0% | 1.1% | 0% | 0% | 0% |
Thromboembolic events (any G) | 2.4% | 1.4% | 0% | 4.3% | 1.8% | 1.2% |